Advances in ADT: Part II: A Guide for Urologists (2023)

September 28, 2023

COMPLIMENTARY CME VIRTUAL COURSE!

September 28, 2023 | Time: 7:00-8:00 PM EDT


Based on the documented need from the AUA Advanced Prostate Cancer Global Needs Assessment, the AUA has created Advances in ADT: Part II: A Guide for Urologists (2023), an educational offering to further update urologists on the latest advancements in androgen deprivation therapy (ADT) and prostate cancer treatment. This educational initiative is comprised of multiple formats, including a live course, on-demand webcast, and a podcast series. This live virtual course, which is the cornerstone of the initiative features a multidisciplinary panel, engaging in a lively discussion. 


ACKNOWLEDGEMENT

Independent educational grant support provided by:

  • Myovant Sciences LTD
  • Pfizer, Inc.

Target Audience

  • Urologists

Learning Objectives

After participating in this educational activity, participants will be able to:

  1. Recognize and characterize different disease states for advance prostate cancer including M0 HSPC, M1 HSPC, M0 CRPC, and M1 CRPC.
  2. Discuss the role of a multidisciplinary shared team approach for the diagnosis and management of advanced prostate cancer.
  3. Facilitate discussions with patients and caregivers regarding treatment intensification for advanced prostate cancer.
  4. Identify the role of combination therapy with ADT and additional systemic therapy to yield optimal survival outcomes for metastatic prostate cancer.
  5. Differentiate mechanisms of action and side effects when ADT is delivered via GnRH agonists vs. antagonists.
Course summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Non-Physician Participation
Course opens: 
07/17/2023
Course expires: 
09/28/2026
Event starts: 
09/28/2023 - 7:00pm EDT
Event ends: 
09/28/2023 - 8:00pm EDT
Rating: 
0

Welcome and Introductions

Pre-test

Segment 1: What is “Advanced Prostate Cancer”?

Segment 2: Combination Therapy and Treatment Intensification

Segment 3: Mechanisms of Action and Side Effects

Segment 4: Talking to Patients and Caregivers about Therapy

Segment 5: Multidisciplinary Shared Team Approach

Post-test

Questions and Answers

Wrap-up

 

***Instructions***

  1. Click on the TAKE COURSE button.
  2. Click “Start” under "Live Virtual Course" in the Course Progress pane.
  3. Click on the link provided to register in advance for this webinar.
  4. After registering, you will receive a confirmation email containing information about joining the webinar. 

EDUCATION COUNCIL DISCLOSURES

PDF iconEducation Council Disclosures

COI REVIEW WORK GROUP DISCLOSURES

PDF iconCOI Review Work Group Disclosures

AUA Office of Education Staff has nothing to disclose.

All relevant financial relationships have been mitigated.

Course Director(s)

Kristen Scarpato, MD

has a financial relationship (Consultant or Advisor (Oncology)) with CxBladder;.
has a financial relationship (Meeting Participant or Lecturer (Oncology)) with Photocure;.
Faculty(s)

Meredith Donahue, MD

has no relevant financial relationships to disclose at this time.

Alicia Morgans, MD

has a financial relationship (Consultant or Advisor (Oncology)) with Telix;.
has a financial relationship (Consultant or Advisor (Oncology)) with Advanced Accelerator Applications;.
has a financial relationship (Consultant or Advisor (Oncology)) with BMS;.
has a financial relationship (Consultant or Advisor (Oncology)) with Janssen;.
has a financial relationship (Consultant or Advisor (Oncology)) with Astra Zeneca;.
has a financial relationship (Consultant or Advisor (General Urology)) with Novartis;.
has a financial relationship (Consultant or Advisor (Oncology)) with Progenics ;.
has a financial relationship (Consultant or Advisor (Oncology)) with Pfizer;.
has a financial relationship (Consultant or Advisor (Oncology)) with Clovis;.
has a financial relationship (Consultant or Advisor (Oncology)) with Astellas;.
has a financial relationship (Consultant or Advisor (Oncology)) with Genetech;.
has a financial relationship (Consultant or Advisor (Oncology)) with Lantheus;.
has a financial relationship (Consultant or Advisor (Oncology)) with Myovant;.
has a financial relationship (Consultant or Advisor (Oncology)) with Dendreon;.
has a financial relationship (Consultant or Advisor (Oncology)) with Sanofi;.
has a financial relationship (Consultant or Advisor (Oncology)) with Myriad;.
has a financial relationship (Consultant or Advisor (Oncology)) with Advanced Accelerator Applications;.
has a financial relationship (Consultant or Advisor (Oncology)) with Merck;.
has a financial relationship (Consultant or Advisor (Oncology)) with Genetech;.
has a financial relationship (Consultant or Advisor (Oncology)) with Bayer;.

ACCREDITATION: 

The American Urological Association (AUA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION: 

The American Urological Association designates this live activity for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

OTHER LEARNERS: 

The AUA is not accredited to offer credit to participants who are not MDs or DOs. However, the AUA will issue documentation of participation that states that the activity was certified for AMA PRA Category 1 Credit™.

EVIDENCE BASED CONTENT: 

It is the policy of the AUA to ensure that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous, and free of commercial bias.

AUA DISCLOSURE POLICY: 

All persons in a position to control the content of an educational activity (i.e., activity planners, presenters, authors) are required to disclose to the provider all financial relationships with any commercial interest (aka ineligible company) during the previous 24 months. The AUA must determine if the individual’s relationships may influence the educational content and mitigate any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners information with which they can make their own judgments.

MITIGATION OF IDENTIFIED CONFLICT OF INTEREST: 

All disclosures will be reviewed by the AUA Conflict of Interest (COI) Review Work Group Chair and/or Vice Chair for identification of conflicts of interest. The AUA COI Review Work Group, working with Office of Education staff, will document the mechanism(s) for management and mitigation of the conflict of interest and final approval of the activity will be documented prior to implementation. Any of the mechanisms below can/will be used to mitigate conflict of interest:

  • Peer review for valid, evidence-based content by the AUA COI Review Work Group.
  • Attestation that clinical recommendations are evidence-based and free of commercial bias.
  • Introduction of a debate format (point-counterpoint)
  • Inclusion of moderated panel discussion with unbiased moderator
  • Publication of a parallel or rebuttal article for an article that is felt to be biased
  • Divestiture of the relationship by faculty
  • Recusal from controlling relevant aspects of planning
  • Selection of alternative faculty for specific topic

OFF-LABEL OR UNAPPROVED USE OF DRUGS OR DEVICES: 

The audience is advised that this continuing medical education activity may contain reference(s) to off-label or unapproved uses of drugs or devices. Please consult the prescribing information for full disclosure of approved uses.

Available Credit

  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Non-Physician Participation
Please login or register to take this course.

Registration for Advances in ADT: Part II: A Guide for Urologists (2023) is complimentary.

To join the live virtual course:

  1. Click on the TAKE COURSE button.
  2. Click “Live Virtual Course” in the Course Progress pane.
  3. Click the link to register in advance.
  4. After registering, you will receive a confirmation email containing information about joining the live virtual course.

Attendee Information & Policies

AUA Anti-Harassment Policy

AUA Commitment: AUA is committed to providing a safe and productive meeting environment that fosters open dialogue and the exchange of scientific ideas and is free of harassment and discrimination. All meeting participants are expected to behave professionally and treat others with respect, follow venue rules, and alert AUA staff or security of any dangerous situations or anyone in distress.

Reporting Harassment: It is the policy of the AUA that all meeting participants will enjoy an environment free from discrimination, harassment or retaliation. Harassing behavior by meeting participants will not be tolerated. If an individual experiences or witnesses harassment, he or she should contact Janet Skorepa, AUA EVP, at jskorepa@AUAnet.org or Maureen E. Cones, Esq., AUA General Counsel, at mcones@auanet.org or use a venue phone and ask for security if he or she feels unsafe. All complaints will be treated seriously and responded to promptly. 

The AUA reserves the right to take any action deemed necessary and appropriate, including refusing or revoking the registration of any individual, without refund, as long as such refusal is consistent with applicable law and AUA policy.

Disclaimer: The opinions and recommendations expressed by faculty, authors and other experts whose input is included in this program are their own and do not necessarily represent the viewpoint of the American Urological Association (AUA).

Consent to Use of Photographic Images: Registration and attendance at or participation in AUA meetings and other activities constitutes an agreement by the registrant to AUA's use and distribution (both now and in the future) of the registrant or attendee's image or voice in photographs, videotapes, electronic reproductions, and audiotapes of such events and activities.

Audio, Video, Photographic Equipment: The use of audio, video and other photographic recording equipment by attendees is prohibited inside AUA meeting rooms.

Reproduction Permission: Reproduction of written materials developed for this AUA course is prohibited without the written permission from individual authors and the AUA.

Special Assistance/Dietary Needs: The AUA complies with the Americans with Disabilities Act §12112(a). If any participant is in need of special assistance or has any dietary restrictions, a written request should be submitted at least one month in advance. For additional assistance with your request please call 1-800-908-9414.